Impairment in marrow function often characterizes the evolution of myelodysplastic syndrome. As a differentiating agent, interferon alpha 2a (INF alpha) has been shown to be active in the correction of cytopenias related to myelodysplastic syndromes (MDS). We report the clinical course of 9 patients with MDS treated with low-dose subcutaneous INF alpha (1 x 10(6), 3 times per week). A significant effect on anemia was only demonstrated in one patient (11%). In the other, eight, therapy was totally ineffective and four of them could not receive the complete treatment due to worsening cytopenias or leukemic transformation. In conclusion, in our study, INF alpha had only limited activity in the treatment of myelodysplastic syndrome.
Galvani David W., Nethersell Anthony B.W., Cawley John C., α-interferon in myelodysplasia; Clinical observations and effects on nk cells, 10.1016/0145-2126(88)90144-0
Blok W L, New England Journal of Medicine, 318, 787 (1988)
Holcombe R F, Leukemia, 7, 192 (1993)
Spielberger Ricardo T., Dickstein Jerome I., Beau Michelle M. Le, Larson Richard A., Daly Karen M., Vardiman James W., Golomb Harvey M., ACUTE MYELOID LEUKAEMIA FOLLOWING INTERFERON-ALFA TREATMENT OF HAIRY CELL LEUKAEMIA, 10.1111/j.1365-2141.1993.tb04680.x
Demeter Judith, Turbucz Piroska, Lehoczky Dezsö, Porzsolt Franz, CONSIDERATIONS ON THE PATHOGENESIS OF ACUTE MYELOID LEUKAEMIA IN A SPLENECTOMIZED HAIRY CELL LEUKAEMIA PATIENT TREATED WITH INTEFERON-ALPHA, 10.1111/j.1365-2141.1994.tb03290.x
Kampmeier P, Blood, 83, 2931 (1994)
Bibliographic reference
Maerevoet, Marie
; Van Den Neste, Eric ; Delannoy, André ; Ferrant, Augustin ; Martiat, P. ; et. al. Limited activity of mini-dose interferon alpha-2a in the treatment of myelodysplastic syndrome.. In: Leukemia & lymphoma, Vol. 21, no. 5-6, p. 519-20 (1996)
